remdesevir - for COVID-19 method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.32 [1.16, 1.50]> 10%4 studies (4 / -)100.0 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 1.49 [1.13, 1.98]> 10%3 studies (3 / -)99.7 %some concernnot evaluable moderatecrucial-
clinical improvement (28-day) 1.64 [1.17, 2.29]> 10%3 studies (3 / -)99.8 %some concernnot evaluable moderatecrucial-
clinical improvement (7-day) 1.23 [0.93, 1.64]> 10%3 studies (3 / -)92.6 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 1.23 [0.87, 1.74]> 10%1 study (1 / -)87.7 %lownot evaluable highcrucial-
deaths 0.75 [0.54, 1.06]< 10%4 studies (4 / -)94.9 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.70 [0.47, 1.04]< 10%1 study (1 / -)96.1 %some concernnot evaluable moderatecrucial-

-- safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1 / -)6.0 %lownot evaluable highimportant-
serious adverse events 0.71 [0.55, 0.92]< 10%2 studies (2 / -)99.5 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 91, 90, 94